PREVIEW: Johnson & Johnson (JNJ) earnings due 25/Jan at 11:25GMT/06:25EST
Johnson & Johnson (JNJ) Q4 2021 (USD): EPS (exp. 2.12/1.77 GAAP), Revenue (exp. 25.29bln)
KEY PHARMA SALES:
- STELARA: (exp. 2.48bln)
- DARZALEX: (exp. 1.58bln)
- IMBRUVICA: (exp. 1.17bln)
- INVEGA SUSTENNA/SUSTENNA: (exp. 1.05bln)
- REMICADE: (exp. 0.78bln)
DIVIDEND:
- Qtrly Dividend: (exp. 0.92)
- FY Dividend: (exp. 4.17)
EPS GUIDANCE:
- Q1 2021 EPS View: (exp. 2.58/2.14 GAAP)
- FY 2021 EPS View: (exp. 9.80/7.81 GAAP)
REVENUE GUIDANCE:
- Q1 2021 Revenue View: (exp. 23.82bln)
- FY 2021 Revenue View: (exp. 94.28bln)
- FY 2022 Revenue View: (exp. 97.79bln)
INDEX WEIGHT:
- 1.2% SPX weight
- 3.2% Dow weight
- Sector/Industry: Health Care/Pharmaceuticals
BROKER RATING:
- Avg Rating: 'Buy'
- Avg Price Target: USD 185.78
- Price Target Changes (last 30 days): 0 upward vs 0 downward
24 Jan 2022 - 17:00- - Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts